Catalyst Pharmaceutical Inc.
Here’s whether Catalyst Pharmaceutical Inc. (CPRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.91% over 10 days); strong 1-year return of +18.3%; 3-month momentum positive (+15.7%); rising volume confirms the move (1.21x 30d avg). Concerns: RSI 78 — overbought, elevated pullback risk. Currently 1.2% off its 52-week high. Score: +6/7.
CPRX is in a confirmed uptrend, trading above both its 50-day ($24.30) and 200-day ($22.39) moving averages. With an RSI of 77.9, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +18.3% compares to +35.1% for SPY (trailed the market by 16.8%).